Benzodiazepines decrease grooming in response to novelty but not ACTH or beta-endorphin.

A J Dunn; A L Guild; N R Kramarcy; M D Ware

doi:10.1016/0091-3057(81)90217-3

Home/Archive/PubMed

PubMed · 6117085

Benzodiazepines decrease grooming in response to novelty but not ACTH or beta-endorphin.

A J Dunn·A L Guild·N R Kramarcy·M D Ware

View original source ↗Export metadata ↓

Abstract

Excessive grooming in response to intracerebroventricular (ICV) ACTH1-24 was assayed following various doses of diazepam, chlordiazepoxide and flurazepam. Grooming scores were only affected by doses of the benzodiazepines higher than those that depressed locomotor activity. Similarly, diazepam did not affect excessive grooming induced by ICV beta-endorphin, nor did chronic chlordiazepoxide affect ACTH-induced grooming. By contrast similar doses of the benzodiazepines decreased the increased grooming score observed when mice were observed in a novel as opposed to the home cage. This result is consistent with the hypothesis that novel cage-induced grooming is caused by an increase in the ventricular content of ACTH or beta-endorphin, and that the benzodiazepines decrease or prevent this increase. It is not consistent with hypotheses of a functional antagonism between ACTH and benzodiazepines, at least insofar as the mechanisms involved in the production of grooming are concerned.

Explore related subjects

Adrenocorticotropic Hormone Animals Anti-Anxiety Agents Chlordiazepoxide Diazepam Drug Interactions Endorphins Environment Grooming Male Mice Time Factors beta-Endorphin Journal Article Research Support, U.S. Gov't, P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

A J Dunn, A L Guild, N R Kramarcy, M D Ware. 1981. Benzodiazepines decrease grooming in response to novelty but not ACTH or beta-endorphin.. https://doi.org/10.1016/0091-3057(81)90217-3

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1996

Role of cortisol in the pathogenesis of deficient counterregulation after antecedent hypoglycemia in normal humans.

The aim of this study was to determine the role of increased plasma cortisol levels in the pathogenesis of hypoglycemia-associated autonomic failure. Experiments were carried out on 16 lean, healthy, overnight fasted male subjects. One group (n = 8) underwent two separate, 2-d randomized experiments separated by at least 2 mo. On day 1 insulin was infused at a rate of 1.5 mU/kg per min and 2 h clamped hypoglycemia (53 +/- 2 mg/dl) or euglycemia (93 +/- 3 mg/dl) was obtained during morning and afternoon. The next morning subjects underwent a 2-h hyperinsulinemic (1.5 mU/kg per min) hypoglycemic (53 +/- 2 mg/dl) clamp study. In the other group (n = 8), day 1 consisted of morning and afternoon 2-h clamped hyperinsulinemic euglycemia with cortisol infused to stimulate levels of plasma cortisol occurring during clamped hypoglycemia (53 mg/dl). The next morning (day 2) subjects underwent a 2-h hyperinsulinemic hypoglycemic clamp identical to the first group. Despite equivalent day 2 plasma glucose and insulin levels, steady state epinephrine, norepinephrine, pancreatic polypeptide, glucagon, ACTH and muscle sympathetic nerve activity (MSNA) values were significantly (R < 0.01) blunted after day 1 cortisol infusion compared to antecedent euglycemia. Compared to day 1 cortisol, antecedent hypoglycemia produced similar blunted day 2 responses of epinephrine, norepinephrine, pancreatic polypeptide and MSNA compared to day 1 cortisol. Antecedent hypoglycemia, however, produced a more pronounced blunting of plasma glucagon, ACTH, and hepatic glucose production compared to day 1 cortisol. We conclude that in healthy overnight fasted men (a) antecedent physiologic increases of plasma cortisol can significantly blunt epinephrine, norepinephrine, glucagon, and MSNA responses to subsequent hypoglycemia and (b) these data suggest that increased plasma cortisol is the mechanism responsible for antecedent hypoglycemia causing hypoglycemia associated autonomic failure.

Adrenocorticotropic Hormone↗

PubMed1996

Regulation of expression of the steroidogenic acute regulatory (StAR) protein by ACTH in bovine adrenal fasciculata cells.

Immunocytochemical studies and immunoblotting analysis demonstrated that there exists the StAR protein in bovine adrenal fasciculata cells, and ACTH activated expression of the StAR protein. Then roles of intracellular signal transduction systems in the regulation of expression of the StAR protein were studied. The addition of Bt2cAMP and forskolin, or phorbol ester plus calcium ionophore 23187 activated expression of the StAR protein as well as cortisol production, suggesting that cyclic AMP- or protein kinase C-dependent process plays a crucial role in the regulation of expression of the StAR protein. Activating effects of ACTH which activates cyclic AMP formation on the StAR protein and cortisol production were inhibited by pretreatment with calphostin C which is a protein kinase C inhibitor, suggesting that ACTH enhances expression of the StAR protein possibly via both of two signal transduction systems such as cyclic AMP- and protein kinase C-dependent processes.

Adrenocorticotropic Hormone↗

PubMed1996

Inferior petrosal sinus sampling in healthy subjects reveals a unilateral corticotropin-releasing hormone-induced arginine vasopressin release associated with ipsilateral adrenocorticotropin secretion.

Arginine vasopressin (AVP) acts synergistically with corticotropin-releasing hormone (CRH) to stimulate ACTH release from the anterior pituitary. In a previous study of bilateral simultaneous inferior petrosal sinus (IPS) sampling in healthy human subjects, we observed lateralized ACTH secretion, suggesting lateralized secretion of an ACTH-regulating hypothalamic factor. To investigate this possibility, we measured ACTH, CRH, AVP, and oxytocin (OT) levels in the IPS and the peripheral circulation in nine normal volunteers, before and after 1 microgram/kg i.v. bolus ovine CRH (oCRH). At baseline, ACTH, AVP, and OT exhibited a significant (P < 0.05) two to threefold intersinus gradient (ISG), indicating the existence of a dominant petrosal sinus. Endogenous CRH was undetectable in all samples. Despite similar exogenous oCRH levels in both petrosal sinuses, oCRH caused a significant increase (P < 0.001) in the ACTH ISG (15.8 +/- 5.6, mean +/- SEM), suggesting increased responsiveness of one dominant side of the anterior pituitary. This was associated with an ipsilateral CRH-induced AVP release and a significant increase (P < 0.01) in the AVP ISG (8.6 +/- 2.3), suggesting lateralized AVP secretion by the hypothalamus. Furthermore, the increased AVP ISG after oCRH correlated strongly with the ACTH ISG (r = 0.92, P < 0.01). oCRH administration did not affect OT. These findings suggest that there is a dominant petrosal sinus in healthy volunteers that appears to reflect a dominant side of the adenohypophysis, characterized by increased functional activity and/or responsiveness of the pituitary corticotrophs. This may reflect lateralized hypothalamic and/or suprahypothalamic function resulting in CRH-responsive lateralized secretion of AVP from parvocellular and/or magnocellular axons in the median eminence and the posterior pituitary. Although the functional and teleologic significance of these findings remains to be investigated, our data suggest a novel mechanism for CRH-mediated ACTH release, namely CRH-induced release of AVP which then enhances CRH action on the corticotrophs. Furthermore, our data represent the first direct evidence for the concept of brain lateralization with respect to neuroendocrine secretion.

Adrenocorticotropic Hormone↗